This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Liver function tests in Graves' disease

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

A study of 30 consecutive patients with Graves' disease investigated the frequency of abnormal liver function tests.

  • values for alkaline phosphatase (AP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma -glutamyltransferase (GGT), and total bilirubin were examined
    • of the 30 study patients, 11 (37%) had at least one abnormal result of a liver function test
    • all patients in the study had determinations of AP (not fractionated), of which 10 values (33%) were above normal
    • all patients had AST levels measured and 5 (17%) had increased values that ranged from 36 to 71 U/L
    • six of the 23 patients (26%) with determinations of ALT had increased values that ranged from 45 to 157 U/L
    • twenty-five patients had measurements of GGT and 6 had above normal results (range, 69 to 331 U/L)
    • two of the 24 patients (8%) with determinations of total bilirubin had increased levels

 

The study authors concluded that the findings indicate that abnormal results of liver function tests are common in patients with hyperthyroidism and make the diagnosis of concomitant, unrelated liver disease difficult until the euthyroid state has been established.

Reference:

  1. Endocr Pract. 2000 Sep-Oct;6(5):367-9

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.